1) Beaulieu JM:A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 37:7-16, 2012
2) Beaulieu JM, Del' guidice T, Sotnikova TD, et al:Beyond cAMP:The Regulation of Akt and GSK3 by Dopamine Receptors. Front Mol Neurosci 4:38, 2011. doi:10.3389/fnmol.2011.00038
3) Emamian ES, Hall D, Birnbaum MJ, et al:Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36:131-137, 2004
4) Hino M, Kunii Y, Matsumoto J, et al:Decreased VEGFR2 expression and increased phosphorylated Akt1 in the prefrontal cortex of individuals with schizophrenia. J Psychiatr Res 82:100-108, 2016
5) 菊山祐貴:第二世代抗精神病薬の気分障害に対する作用機序.医学のあゆみ 227:519-523, 2008
6) Mulder SF, Bertens D, Desar IM, et al:Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients:a cross sectional study. BMC Cancer 14:219, 2014. doi:10.1186/1471-2407-14-219
7) Noble W, Planel E, Zehr C, et al:Inhibition of glycogen synthase kinase-3 y lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Sci U S A 102:6990-6995, 2005
8) Schellekens AF, Mulder SF, van Eijndhoven PF, et al:Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases. Gen Hosp Psychiatry 33:83 e1-e3, 2011. doi:10.1016/j.genhosppsych.2010.09.008
9) Zhang H, Liu ZL, Sun P, et al:Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration. Acta Ophthalmol 90:e647-e648, 2012. doi:10.1111/j.1755-3768.2012.02421.x